Pharming Group

Pharming Group Current Liabilities

The Current Liabilities of Pharming Group (PHAR) as of Oct 15, 2026 is 115.79 M USD. In the previous year, Current Liabilities was 73.02 M USD — a change of 58.57% (higher).

Current Liabilities

115.79 MUSD

YoY

58.57%

Last updated:

Current Liabilities of Pharming Group is 2025 115.79 M USD. Current Liabilities of Pharming Group was 2024 73.02 M USD. It decreases by 58.57% higher compared to the previous year.

The Pharming Group Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
79.23 M USD
Jan 1, 2019
114.46 M USD
Jan 1, 2020
62.91 M USD
Jan 1, 2021
51.32 M USD
Jan 1, 2022
57.60 M USD
Jan 1, 2023
71.73 M USD
Jan 1, 2024
73.02 M USD
Jan 1, 2025
115.79 M USD
The Pharming Group Current Liabilities history
YEARCurrent LiabilitiesYoY
115.79 MUSD+58.57%
73.02 MUSD+1.79%
71.73 MUSD+24.54%
57.60 MUSD+12.24%
51.32 MUSD-18.42%
62.91 MUSD-45.04%
114.46 MUSD+44.46%
79.23 MUSD+14.41%
69.25 MUSD+31.13%
52.81 MUSD+386.42%
10.86 MUSD-28.81%
15.25 MUSD+4.79%
14.56 MUSD+61.26%
9.03 MUSD-14.39%
10.54 MUSD-18.13%
12.88 MUSD-75.22%
51.97 MUSD+197.44%
17.47 MUSD-25.92%
23.58 MUSD+94.38%
12.13 MUSD+82.54%
6.65 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV is a biopharmaceutical company based in Leiden, Netherlands, listed on the stock market with the ticker PHAR and ISIN US71716E1055. The company operates in the Health Care sector, specifically within the Health Care industry, and employs approximately 1,800 people. Pharming Group NV went public through an IPO on December 23, 2020. Its website is https://www.pharming.com. The company focuses on developing and commercializing protein replacement therapies and precision medicines for rare diseases. While the provided source mentions specific products like RUCONEST and Joenja, these details are treated as untrusted facts and are not included in this profile. Pharming Group NV is incorporated in the United States, though it is headquartered in Leiden, Netherlands. The company has a development collaboration and license agreement with Novartis, as noted in the source. Pharming Group NV's activities span the United States, Europe, and internationally. The company's primary focus is on rare diseases, and it is engaged in the research, development, and commercialization of innovative therapeutic solutions. The company's corporate structure and operations are centered around its headquarters in Leiden, with a global reach in the healthcare market. The exact founding year is not provided in the user message, so it is omitted from this profile. The company's product pipeline and specific therapeutic areas are not detailed beyond the general focus on rare diseases. Pharming Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharming Group stock

Current Liabilities of Pharming Group is 115.79 M USD in 2025.

Current Liabilities of Pharming Group changed from 73.02 M USD to 115.79 M USD, representing a 58.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Pharming Group since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Pharming Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Pharming Group

All Key Metrics — Pharming Group